HCPLive

$name$

Latest Headlines

Hepatitis C: Testing Has a Long Way to Go
The explosion in new drugs to treat hepatitis C is leading to predictions the viral infection will no longer be a major health problem. But before that can happen, much has to be done in the realm of public health, researchers said April 25 at the International Liver Congress in Vienna, Austria.
Alchohol Use Predicts Hepatitis C Deaths
In addition to injection drug use, alcohol consumption puts people at risk of dying from hepatitis C infection by increasin the severity of the disease. A French research study spells out the risks.
Multiple Sclerosis, Crohn’s Drug Used in HIV Targeted Therapy
Natalizumab, a drug typically used to treat multiple sclerosis and Crohn’s disease, has been shown to be effective in treating animal models of HIV.
Tocilizumab Reduces LDL-C in Patients with Rheumatoid Arthritis
LDL-C was reduced in RA patients who took tocilizumab compared to placebo in a study published in Annals of the Rheumatic Diseases.
Stress is a Product of and Cause of Inequality
Stress is both a cause of and product of inequality, according to a study published in Psychoneuroendocrinology.
Weaning Transplant Patients from Immunosuppressive Drugs
The assumption used to be that after a liver transplant patients would need to take immunosuppressive drugs for years, even for life. A team of German researchers say that for about half of adult patients, that is no longer true.
ALLY-1 Results: More Good News on Hep C
As good news about new treatments for hepatitis C infections continues to dominate the 2015 International Liver Congress, Texas researchers today reported more success with sofosbuvir and daclatasvir.

Most Popular

$vacMongoViewPlus$ $vAR$